Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
Clinical practice guidelines
Early disease
Locally advanced disease
Non-small cell lung cancer
Recommendations
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
25
10
2019
revised:
11
12
2019
accepted:
26
12
2019
pubmed:
18
2
2020
medline:
9
4
2020
entrez:
17
2
2020
Statut:
ppublish
Résumé
The Italian Association of Medical Oncology (AIOM) has developed clinical practice guidelines for the diagnosis and treatment of patients with early and locally advanced non-small cell lung cancer. In the current paper a panel of AIOM experts in the field of thoracic malignancies discussed these topics, analyzing available scientific evidences, with the final aim of providing a summary of clinical recommendations, which may guide physicians in their current practice.
Identifiants
pubmed: 32062311
pii: S1040-8428(19)30248-3
doi: 10.1016/j.critrevonc.2019.102862
pii:
doi:
Types de publication
Journal Article
Practice Guideline
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102862Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Silvia Novello, Department of Oncology, University of Turin, AOU San Luigi, Orbassano (Italy). COI: consultant and/or speaker's fee for Eli Lilly, MSD, Roche, BMS, Takeda, Pfizer, Abbvie, Celgene, AZ, Boehringer Ingelheim.